
 |
|
 |
 |
 |
Approval Expanded for Breast Cancer Drug Tykerb (HealthDay)
HealthDay - MONDAY, Feb. 1 (HealthDay News) -- The U.S. Food and Drug
Administration has expanded approval for Tykerb (lapatinib) to include
postmenopausal women with hormone- and HER2-positive advanced breast
cancer who require hormone therapy. |
|
|
 |